Oculis Acquires Privosegtor to Expand Neuro-Ophthalmology
Zug, Switzerland & Barcelona, Spain, August 10, 2026 Oculis Holding AG and Accure Therapeutics S.L. have entered into an...
FDA Breakthrough Therapy
Advertisement
Compass Pathways Partners with VA to Evaluate COMP360 for Treatment-Resistant Depression
LONDON & NEW YORK, August 6, 2026 Definium Therapeutics reported its second quarter 2026 financial results and recent business...
Amylyx Pharmaceuticals Advances Avexitide Toward Phase 3 Data
CAMBRIDGE, Mass., August 6, 2026 Amylyx Pharmaceuticals reported its second quarter 2026 financial results, highlighting significant progress across its...
Roche’s Divarasib Beats Approved KRAS Therapies in Phase III Trial
Basel, Switzerland, July 2, 2026 Roche has announced positive top-line results from its pivotal Phase III Krascendo 1 clinical...
Pfizer’s HYMPAVZI Gains FDA Approval for Expanded Hemophilia Care
NEW YORK, USA – June 8, 2026 Pfizer has secured U.S. Food and Drug Administration (FDA) approval for an...
Advertisements
GSK to Acquire Nuvalent in $10.6B Lung Cancer Expansion
LONDON, United Kingdom & BOSTON, Massachusetts, USA – June 8, 2026 GSK has announced a definitive agreement to acquire...
Incyte to Acquire Vega Therapeutics for $2 Billion Deal
WILMINGTON, Delaware, USA – June 8, 2026 Incyte Corporation has announced a definitive agreement to acquire Vega Therapeutics, a...
Boehringer’s Survodutide Delivers Major Metabolic Benefits
INGELHEIM, Germany – June 7, 2026 Boehringer Ingelheim has reported positive Phase III results for its investigational glucagon/GLP-1 dual...
Servier Advances OJEMDA Front-Line Brain Cancer Trial
BOSTON – May 8, 2026 Day One Biopharmaceuticals, now part of Servier Group, announced the completion of patient enrollment...
FDA Breakthrough Status for Lilly’s Sofetabart Mipitecan ADC
Indianapolis, January 20, 2026 — Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has...
Advertisement
